JonesResearch downgraded Intellia Therapeutics (NTLA) to Hold from Buy after the company reported along with Q3 results on November 6 that the nex-z treated patient who hit Hy’s Law criteria had passed away. While both lonvo-z for HAE and nex-z for ATTR-CM have durable efficacy, the firm says heightened safety risk and lack and lack of clarity, as well as other market dynamics, prompt it to move to the sidelines.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Intellia Therapeutics downgraded to In Line from Outperform at Evercore ISI
- Intellia Reports Favorable Phase 1 Data for Nex-Z
- Intellia announces ‘positive’ follow-up data from ongoing Phase 1 nex-z trial
- Intellia Therapeutics price target lowered to $14 from $25 at Truist
- Cathie Wood Sells Tesla (TSLA) Stock, and Buys This Stock after Q3 Beat